| Concerning FDA approval of trilaciclib (Cosela) in extensive-stage small-cell lung cancer K Powell, V Prasad Translational Oncology, 2021 | 16 | 2021 |
| The Oncologic Drugs Advisory Committee Votes of April 2021—Implications for the Fate of Accelerated Approval K Powell, MP Lythgoe, V Prasad JAMA oncology, 2021 | 14 | 2021 |
| Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial T Olivier, K Powell, V Prasad European Urology, 2022 | 8 | 2022 |
| Characteristics of Oncology Podcasts: Attitudes, Speakers, Conflicts E Greenstreet Akman, K Powell, A Haslam, V Prasad Journal of Cancer Policy, 2022 | 7 | 2022 |
| The noble lies of COVID-19 K Powell, V Prasad Future Tense. https://slate. com/technology/2021/07/noble-lies-covid-fauci …, 2021 | 6 | 2021 |
| Where are randomized trials necessary: Are smoking and parachutes good counterexamples? K Powell, V Prasad European Journal of Clinical Investigation, 2021 | 5 | 2021 |
| Idecabtagene vicleucel: questions regarding the appropriate role and cost K Powell, D Russler-Germain, V Prasad British Journal of Haematology, 2021 | 5 | 2021 |
| Financial conflicts of interest of OncoAlert: An informal oncology professional network K Powell, A Kakkilaya, A Haslam, V Prasad Journal of Cancer Policy 34, 100369, 2022 | 4 | 2022 |
| Eventual success rate and predictors of success for oncology drugs tested in phase I trials A Haslam, T Olivier, K Powell, T Jordan, V Prasad International Journal of Cancer, 2022 | 3 | 2022 |
| Interpreting the results from the first randomised controlled trial of colonoscopy: does it save lives? K Powell, V Prasad BMJ Evidence-Based Medicine 28 (5), 306-308, 2023 | 2 | 2023 |
| The role of surgery in metastatic cancer: the case for a pragmatic tumor-agnostic randomized trial K Powell, J Marquart, T Olivier, V Prasad Future Oncology, 2023 | 2 | 2023 |
| Financial conflicts of interest of physicians followed by neurosurgical journals on Twitter K Powell, K McCall, K Hooda, V Prasad, A Kakkilaya International Journal of Health Planning and Management, 2023 | 2 | 2023 |
| How often do medical specialties question the practices that they perform? An empirical, cross-sectional analysis of the published literature A Haslam, K Powell, V Prasad INQUIRY: The Journal of Health Care Organization, Provision, and Financing …, 2022 | 2 | 2022 |
| Relugolix: Five Reasons Why the US Food and Drug Administration Should Have Exercised Restraint K Powell, M Burns, V Prasad European Urology, 2022 | 2 | 2022 |
| The Kardashian Index: a study of researchers' opinions on twitter 2014–2021 K Powell, A Haslam, V Prasad Scientometrics, 2022 | 2 | 2022 |
| A novel trial methodology to test interventions with very large effect sizes: the case of dostarlimab in mismatch repair-deficient, locally advanced rectal cancer K Powell, T Olivier, V Prasad Trials, 2022 | 1 | 2022 |
| Common misconceptions of randomized controlled trials in oncology K Powell, V Prasad European Journal of Clinical Investigation 52 (11), e13832, 2022 | 1 | 2022 |
| Multiplicity: When many analytic plans are applied or many redundant studies are run, false‐positive results are ensured K Powell, V Prasad European Journal of Clinical Investigation 52 (8), e13802, 2022 | 1 | 2022 |
| Colorectal cancer screening at a younger age: pitfalls in the model-based recommendation of the USPSTF K Powell, V Prasad BMJ Evidence-Based Medicine, 2021 | 1 | 2021 |
| Financial conflicts of interest of physicians followed by oncology journals on Twitter C Betts, A Kakkilaya, S Vasireddy, N Arora, V Prasad, K Powell Journal of Cancer Research and Clinical Oncology 149 (15), 14137-14144, 2023 | | 2023 |
Vinay Prasad, MD MPHProfessor, University of California San FranciscoVerified email at ucsf.edu
